{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:36:00Z","timestamp":1791909360941,"version":"4.3.4"},"reference-count":22,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T00:00:00Z","timestamp":1645747200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cytometry Part B Clinical"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The expression pattern of common antigens including cytoplasmic kappa\/lambda ratio (cyKLR) was evaluated by flow cytometric immunophenotyping (FCMI) to explore their relevance in discriminating normal and aberrant plasma cells (NPC and APC, respectively) across spectrum of plasma cell proliferative disorders (PCPD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this prospective analysis, 791 samples from PCPD (treatment naive\u00a0=\u00a0455; partially treated\u00a0=\u00a0336) were evaluated for expression of CD38, CD138, CD45, CD19, CD56, CD27, CD81, CD117, Cy\u2010kappa, and Cy\u2010lambda using FCMI.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Amongst the entire cohort, 20.7% (<jats:italic>n<\/jats:italic>\u00a0=\u00a0164) samples displayed only APC, 21% (<jats:italic>n<\/jats:italic>\u00a0=\u00a0165) only NPC and 58% (<jats:italic>n<\/jats:italic>\u00a0=\u00a0462) showed coexistence of NPC and APC. Using pattern\u2010based recognition (PBR) for three common patterns (CD19 vs. CD56; CD27 vs. CD56 and CD19 vs. CD27), APC was separable from NPC in 93% samples. In 6.5% samples, the gating markers contributed in APC\u2013NPC differentiation and in the remaining 0.5% CD117 and CD81 proved useful. Clonality assessment was found to be crucial to label plasma cell compartment as completely normal or aberrant in 42% cases with either all NPC or all APC. Sixty one out of 462 cases (13%) revealed cyKLR within normal reference range and in these cases; abnormal cyKLR was demonstrable only after gating APC separately based on PBR.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Fair discrimination between NPC and APC is achievable in all PCPD samples using eight markers (Gating: CD38, CD138, CD45; PBR:CD19, CD56, CD27; clonality: Cy\u2010kappa and Cy\u2010lambda). Thus, combined assessment of clonality and immunophenotypic aberrancies is required for accurate, reliable and precise assessment of NPC and APC compartments in PCPD.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cyto.b.22062","type":"journal-article","created":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T09:14:43Z","timestamp":1645780483000},"page":"292-302","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Flow cytometric immunophenotyping of plasma cells across the spectrum of plasma cell proliferative disorders: A fresh insight with pattern\u2010based recognition"],"prefix":"10.1002","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7025-6210","authenticated-orcid":false,"given":"Nupur","family":"Das","sequence":"first","affiliation":[{"name":"Department of Laboratory Oncology Dr. B.R. Ambedkar IRCH, All India Institute of Medical Sciences (AIIMS)  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meetu","family":"Dahiya","sequence":"additional","affiliation":[{"name":"Department of Laboratory Oncology Dr. B.R. Ambedkar IRCH, All India Institute of Medical Sciences (AIIMS)  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5364-4086","authenticated-orcid":false,"given":"Ritu","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Laboratory Oncology Dr. B.R. Ambedkar IRCH, All India Institute of Medical Sciences (AIIMS)  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Rai","sequence":"additional","affiliation":[{"name":"Department of Laboratory Oncology Dr. B.R. Ambedkar IRCH, All India Institute of Medical Sciences (AIIMS)  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saroj","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Laboratory Oncology Dr. B.R. Ambedkar IRCH, All India Institute of Medical Sciences (AIIMS)  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay K.","family":"Prajapati","sequence":"additional","affiliation":[{"name":"Department of Laboratory Oncology Dr. B.R. Ambedkar IRCH, All India Institute of Medical Sciences (AIIMS)  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalit","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dr. B.R. Ambedkar IRCH, All India Institute of Medical Sciences (AIIMS)  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dr. B.R. Ambedkar IRCH, All India Institute of Medical Sciences (AIIMS)  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjit K.","family":"Sahoo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dr. B.R. Ambedkar IRCH, All India Institute of Medical Sciences (AIIMS)  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Gogia","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dr. B.R. Ambedkar IRCH, All India Institute of Medical Sciences (AIIMS)  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,2,25]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21228"},{"key":"e_1_2_8_3_1","first-page":"1234","article-title":"The phenotype of normal, reactive and malignant plasma cells. Identification of \u201cmany and multiple myelomas\u201d and of new targets for myeloma therapy","volume":"91","author":"Bataille R.","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0531"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.12411"},{"key":"e_1_2_8_6_1","unstructured":"DasN. DahiyaM. GuptaR. KumarL. SharmaA. RaiS. SinghS. PrajapatiV. K. SahooR. K.&GogiaA.(2021)Relevance of polyclonal plasma cells and post\u2010therapy immunomodulation in MRD assessment in multiple myeloma."},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404284"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21265"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.29"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1309\/AJCP1GYI7EHQYUYK"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.122"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.1.340.340_340_345"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190412331283279"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1309\/74R4TB90BUWH27JX"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.4120"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/1746-1596-7-131"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21269"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11080"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016003715"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.5858\/2007-131-951-QOPCIB"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb05244.x"}],"container-title":["Cytometry Part B: Clinical Cytometry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cyto.b.22062","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cyto.b.22062","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cyto.b.22062","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T07:13:16Z","timestamp":1692947596000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cyto.b.22062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,25]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1002\/cyto.b.22062"],"URL":"https:\/\/doi.org\/10.1002\/cyto.b.22062","archive":["Portico"],"relation":{},"ISSN":["1552-4949","1552-4957"],"issn-type":[{"value":"1552-4949","type":"print"},{"value":"1552-4957","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,25]]},"assertion":[{"value":"2021-08-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}